BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• BioNTech has a “Moderate Buy” consensus rating from 19 analysts: 13 rate it a buy, one a strong buy, four hold, and one sell. The average 12-month price target is $127.44.
• Recent analysts generally remain positive but have lowered their targets, including Citigroup to $125, Berenberg to $140, and Canaccord Genuity to $136; Wall Street Zen downgraded the stock to sell.
• BioNTech reported a quarterly loss of $2.53 per share and revenue of $122.31 million, missing estimates and marking a 59.5% year-over-year revenue decline. Shares opened at $103.76, while institutional investors own 15.52% of the stock.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nineteen research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, thirteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $127.4375.

BNTX has been the topic of a number of recent research reports. Citigroup cut their price objective on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating on the stock in a report on Wednesday, August 5th. Berenberg Bank lowered their target price on shares of BioNTech from $155.00 to $140.00 and set a "buy" rating for the company in a report on Tuesday, May 12th. Wall Street Zen cut BioNTech from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Sanford C. Bernstein restated a "market perform" rating on shares of BioNTech in a research note on Friday, June 5th. Finally, Canaccord Genuity Group reduced their price objective on BioNTech from $142.00 to $136.00 and set a "buy" rating for the company in a research report on Monday, August 31st.

BioNTech Stock Performance

Shares of BNTX stock opened at $103.76 on Tuesday. BioNTech has a 12 month low of $79.52 and a 12 month high of $124.00. The stock has a market cap of $26.24 billion, a PE ratio of -13.25 and a beta of 1.29. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The company's fifty day moving average price is $96.82 and its 200-day moving average price is $95.61.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business had revenue of $122.31 million during the quarter, compared to analysts' expectations of $180.18 million. During the same period in the prior year, the company earned ($1.60) earnings per share. The firm's quarterly revenue was down 59.5% compared to the same quarter last year. On average, equities analysts expect that BioNTech will post -6.33 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several institutional investors and hedge funds have recently modified their holdings of BNTX. Flossbach Von Storch SE bought a new position in BioNTech in the 2nd quarter valued at approximately $207,142,000. GSK plc purchased a new stake in BioNTech during the 4th quarter valued at $84,711,000. BNP Paribas Financial Markets increased its holdings in shares of BioNTech by 43.0% in the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock worth $150,235,000 after purchasing an additional 474,796 shares in the last quarter. First Trust Advisors LP increased its holdings in shares of BioNTech by 116.0% in the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock worth $74,658,000 after purchasing an additional 451,124 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of BioNTech by 344.4% in the 3rd quarter. Bank of America Corp DE now owns 573,356 shares of the company's stock worth $56,544,000 after purchasing an additional 444,332 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.